港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元_老虎社区_美港股上老虎

港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元

智通财经网2022-04-01

智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。

消息面上，中国生物制药公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要驱动力来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，公司拟投入不超过10亿港元用于回购及员工持股计划。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

淡泊_9570
·2022-04-01
因为老板太抠门分红太少！
回复
点赞
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2224703397?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20220401/20220401093900_56648.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2022-04-01 09:38","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2224703397","market":"us","top_or_hot":-1,"title":"港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元","media":"智通财经网","content":"<html><body><div> <p>智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。</p><p>消息面上，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要<a href=\"https://laohu8.com/S/838275\">驱动力</a>来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，公司拟投入不超过10亿港元用于回购及员工持股计划。</p> </div></body></html>","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-01 09:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/694885.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。消息面上，中国生物制药公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要驱动力来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/694885.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/694885.html","article_id":"2224703397","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20220401/20220401093900_56648.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2224703397","pubTimestamp":1648777110,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01477":"欧康维视生物-B","01177":"中国生物制药","BK1515":"抗疫概念","BK1191":"制药","BK1589":"北水核心资产","BK1521":"挪威政府全球养老基金持仓","BK1574":"生物医药B类股"},"translate_title":"Hong Kong stocks changed Zhongsheng Pharmaceutical (01177) and fell nearly 7% after the performance. The annual net profit increased by 427.2% year-on-year to 14.61 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"01477":1},"content_text":"智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。消息面上，中国生物制药公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要驱动力来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，公司拟投入不超过10亿港元用于回购及员工持股计划。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":610734356,"gmtCreate":1648777855802,"gmtModify":1648777855802,"author":{"id":"3522637711373744","authorId":"3522637711373744","name":"淡泊_9570","avatar":"https://static.tigerbbs.com/c542ce8de487057df4a50c98200982d3","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3522637711373744","authorIdStr":"3522637711373744"},"htmlText":"因为老板太抠门分红太少！","listText":"因为老板太抠门分红太少！","text":"因为老板太抠门分红太少！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/610734356","repostId":2224703397,"repostType":2,"repost":{"id":"2224703397","kind":"highlight","pubTimestamp":1648777110,"share":"https://www.laohu8.com/m/news/2224703397?lang=&edition=full","pubTime":"2022-04-01 09:38","market":"us","language":"zh","title":"港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2224703397","media":"智通财经网","summary":"中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。","content":"<html><body><div> <p>智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。</p><p>消息面上，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要<a href=\"https://laohu8.com/S/838275\">驱动力</a>来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，公司拟投入不超过10亿港元用于回购及员工持股计划。</p> </div></body></html>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 中生制药(01177)绩后倒跌近7% 年度纯利同比增长427.2%至146.1亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-01 09:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/694885.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。消息面上，中国生物制药公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要驱动力来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/694885.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/image/20220401/20220401093900_56648.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","relate_stocks":{"01477":"欧康维视生物-B","01177":"中国生物制药","BK1515":"抗疫概念","BK1191":"制药","BK1589":"北水核心资产","BK1521":"挪威政府全球养老基金持仓","BK1574":"生物医药B类股"},"source_url":"http://www.zhitongcaijing.com/content/detail/694885.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2224703397","content_text":"智通财经APP获悉，中生制药(01177)绩后倒跌逾7%，截至发稿，跌6.95%，报4.55港元，成交额3987.35万港元。消息面上，中国生物制药公告，2021年营业收入268.6亿元，同比增长13.6%，净利润146.1亿元，同比增长427%。公司业绩增长的主要驱动力来自与北京科兴合营公司科兴中维新冠疫苗的销售，中生制药持有科兴中维15.03%的股份，为中生制药带来136.3亿元盈利。此外，公司拟投入不超过10亿港元用于回购及员工持股计划。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}